Moderna (MRNA) Stock Surges 3.6% Following Melanoma Trial Win and COVID Vaccine Green Light

Quick Summary

• Shares of Moderna climbed 3.6% Tuesday, reaching approximately $145.40 amid lower-than-usual trading activity.
• Encouraging Phase 3 data for a personalized mRNA melanoma vaccine developed with Merck boosted investor sentiment.
• U.S. regulators granted approval for Moderna’s latest COVID-19 vaccine formulation.
• Analyst consensus sits at “Hold” with a mean price target of $80.53, significantly below current share prices.
• Competition looms as GSK progresses its mRNA influenza vaccine into late-stage trials.

Shares of Moderna experienced a 3.6% uptick Tuesday, peaking at $143.74 during the session before settling near $145.40. Trading activity remained subdued with approximately 2.4 million shares changing hands, representing a 79% decline from the typical daily volume exceeding 11 million.

Moderna, Inc., MRNA

The upward movement stemmed from two significant developments. Initially, Moderna alongside Merck unveiled promising late-stage trial outcomes for their customized mRNA-based melanoma vaccine. These results strengthened expectations that Moderna’s cancer treatment pipeline might evolve into a substantial revenue source beyond its COVID franchise.

Additionally, United States health authorities greenlit Moderna’s refreshed COVID-19 vaccine formulation, providing the biotech firm with a market-ready product as the fall respiratory illness season approaches.

This dual announcement propelled shares upward while maintaining investor attention on Moderna’s diversified development portfolio.

Wall Street Maintains Cautious Stance

Notwithstanding Tuesday’s advance, analyst sentiment remains measured. The prevailing consensus among Wall Street professionals stands at “Hold,” accompanied by a mean price objective of $80.53—substantially beneath current trading levels.

Multiple prominent financial institutions have adjusted their projections higher recently, yet most maintain reserved positions. JPMorgan elevated its target from $40 to $77 while preserving an “underweight” recommendation. Morgan Stanley increased its objective from $39 to $89 but retained an “equal weight” stance. Bank of America upgraded its rating from “underperform” to “neutral.”

Loop Capital established a $135 price objective, representing the closest alignment with current valuations among major brokerages. Brookline Capital Markets maintained its “Buy” recommendation and continues projecting profitability for 2029 and 2030, despite modest downward revisions to earnings-per-share forecasts for those periods.

Among 23 analysts tracking the stock, seven assign Buy ratings, thirteen recommend Hold positions, and three advise Sell.

GSK Emerges as Competitive Challenge

An emerging risk factor involves GSK. The pharmaceutical powerhouse has advanced its proprietary mRNA influenza vaccine into Phase III development, entering this therapeutic arena shortly after Moderna secured the initial U.S. regulatory approval for a seasonal flu mRNA vaccine.

While that clearance represented a significant achievement for Moderna, GSK’s entrance into this market segment introduces questions regarding Moderna’s potential market dominance over time.

Regarding financial performance, Moderna’s latest quarterly disclosure on July 31 revealed a per-share loss of $1.97, surpassing expectations of a $2.03 deficit. Revenue totaled $145 million, exceeding analyst projections of $102.9 million and representing a 2.1% year-over-year increase.

The organization finalized a $2.6 billion convertible notes transaction, bolstering its capital reserves for ongoing clinical initiatives. Moderna maintains a modest debt-to-equity ratio of 0.09 and a current ratio of 2.29, affording considerable near-term financial maneuverability.

Moderna has additionally announced scheduled presentations at the Morgan Stanley Global Healthcare Conference on September 14 and the Bernstein Healthcare Forum on September 23.

Since the beginning of the year, MRNA stock has surged approximately 376%.